Project Grant R01HL175058
- This $229,608 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research investigating the role of pleural mesothelial cells in lung injury, repair, and regeneration. The award to Mayo Clinic aims to conduct lineage-tracing experiments in mouse models of lung injury and regeneration, and subsequent genomic analysis of the collected pleural mesothelial cells. This research seeks to improve the understanding of repair...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $729,703 to The Trustees of Columbia University in the City of New York to develop a technology called "NanoVials" to sort and enrich mesenchymal stem cells (MSCs) based on their extracellular vesicle (EV) secretion levels. The goal is to optimize stem cell therapies for ischemic diseases like myocardial infarction by identifying and utilizing MSCs with...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research into the role of post-transcriptional RNA modifications in lung development and regeneration. The $768,985 award, effective September 1, 2025 through June 30, 2029, will enable researchers at Columbia University's Health Sciences Division to study how the METTL3/14 complex-mediated RNA modifications, including on the SOX9 transcript, regulate lung...
- This Project Grant award for $814,387 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is supporting research to investigate the role of a novel subpopulation of innate lymphoid cells (ILC3s) in lung infections and vascular regeneration. The award recipient, The Trustees of Columbia University, will utilize mouse models, single-cell analysis, and in vitro assays to: Define the tissue niche and response dynamics of lung vascular ILC3s (VILC3s),...
- This federal Project Grant award of $248,999 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research on mesenchymal cell plasticity and signaling in lung regeneration. The award aims to examine how specific mesenchymal cell lineages establish and maintain maladaptive epithelial regeneration after severe lung injury, such as from influenza or COVID-19. Key objectives include investigating the proliferation, plasticity, and Notch...
- The National Heart Lung and Blood Institute awarded a $719,882 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) to elucidate lung-specific immune pathways driving post-hematopoietic cell transplant lung injury in children. The research aims to identify cellular and molecular targets for precision diagnostics and therapeutics. Specifically, the project will leverage bronchoalveolar lavage fluid...
- This federal Project Grant award for $637,913, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research by the University of Southern California (USC) to investigate the role of "transitional alveolar epithelial cells" in lung development and regeneration. The goal is to better understand the mechanisms underlying the alveolar epithelial cell differentiation process during normal lung development, as...
- The federal Project Grant award titled "Targeting the Stromal Niche for Tissue-Resident Lymphocytes in Asthma" was provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The $636,843 award will fund research to characterize a targetable stromal factor that alters immune cell accumulation in the lung and define the downstream effects on airway epithelial cells. The project aims to leverage novel genetic tools, human...
- This Project Grant award for $744,880.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate how lactate produced by alveolar epithelial type II cells can shift alveolar macrophages towards an anti-inflammatory phenotype, which could enable therapeutic exploitation of this innate protective mechanism in acute lung injury and acute respiratory distress syndrome. The...
- This $721,826 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify molecular mechanisms regulating alveolar matrix fibroblast function and their role in supporting vascular capillary formation. The research is being conducted by Children's Hospital Medical Center in Cincinnati, Ohio to advance the understanding of alveolar septation and septal wall maturation, which is...
The federal Project Grant award, titled "Intravenously Injected Mesenchymal Stromal Cells Protect Against Acute Lung Injury by Transferring Mitochondria to Restore Endothelial Function", was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $761,262 award, granted on Sep 1, 2025, supports research to define the mechanisms by which bone marrow-derived mesenchymal stromal cells (BMSCs) can protect against acute lung injury (ALI) through mitochondrial transfer to endothelial cells. The research, conducted by The Trustees of Columbia University in the City of New York, aims to evaluate BMSC attachment to lung endothelium and the barrier-protective effects of BMSC-to-endothelial mitochondrial transfer, with the ultimate goal of developing improved BMSC-based therapies for ALI.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $761.3k | 8/17/25 |